Page 1074 - medicina-integrativa_compress

CAPÍTULO 106 UNA MIRADA SELECTIVA A LAS INTERACCIONES ENTRE FÁRMACOS Y MEDICINA NATURAL 1103

22. Markowitz JS, Donovan JL, DeVane CL, et al: Effect of St. John’s 39. Johne A, Brockmoller J, Bauer S, et al: Pharmacokinetic interaction
wort on drug metabolism by induction of cytochrome P450 3A4 of digoxin with an herbal extract from St John’s wort (Hypericum
enzyme. JAMA 290:1500-1504, 2003. perforatum). Clin Pharmacol Ther 66:338-345, 1999.
23. Ladner DP, Klein SD, Steiner RA, Walt H: Synergistic toxicity of 40. Beckman SE, Sommi RW, Switzer J: Consumer use of St. John’s
delta-aminolaevulinic acid-induced protoporphyrin IX used for wort: A survey of effectiveness, safety, and tolerability.
photodiagnosis and Hypericum extract, a herbal antidepressant. Pharmacotherapy 20:568-574, 2000.
Br J Dermatol 144:916-918, 2001. 41. Wang Z, Hamman MA, Huang SM, et al: Effect of St. John’s wort
24. Roots I, Johne A, Schmider J, Brockmoller J, et al: Interaction on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther
of a herbal extract from St. John’s wort with amitriptyline and its 71:414-420, 2002.
metabolites [abstract PIII-69]. Clin Pharmacol Ther 67:159, 2000. 42. Frye RF, Fitzgerald SM, Lagattuta TT, et al: Effect of St. John’s wort
25. Durr D, Stieger B, Kullak-Ublick GA, et al: St. John’s wort induces on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther
intestinal P-glycoprotein/MDR1 and intestinal and hepatic 76:323-329, 2004.
CYP3A4. Clin Pharmacol Ther 68:598-604, 2000. 43. Mathijssen RH, Verweij J, de Bruijn P, et al: Effects of St. John’s wort
26. Miller LG: Herbal medicinals: Selected clinical considerations on irinotecan metabolism. J Natl Cancer Inst 94:1247-1249, 2002.
focusing on known or potential drug-herb interactions. Arch Intern 44. Muller WE, Singer A, Wonnemann M, et al: Hyperforin represents
Med 158:2200-2211, 1998. the neurotransmitter reuptake inhibiting constituent of Hypericum
27. Upton R (ed): St. John’s Wort, Hypericum perforatum: Quality extract. Pharmacopsychiatry 31:16-21, 1998.
Control: Analytical and Therapeutic Monograph. Santa Cruz, Calif., 45. Singer A, Wonnemann M, Muller WE: Hyperforin, a major
American Herbal Pharmacopoeia, 1997, pp 1-32. antidepressant constituent of St. John’s wort, inhibits serotonin
28. Lau WC, Carville DGM, Guyer KE, et al: St. John’s Wort Enhances uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther
the Platelet Inhibitory Effect of Clopidogrel in Clopidogrel 290:1363-1368, 1999.
“Resistant” Healthy Volunteers [Presentation 1043-129]. Presented 46. Hussain MD, Teixeira MG: Saint John’s wort and analgesia: Effect of
at American College of Cardiology Annual Meeting, March 6-9, Saint John’s wort on morphine induced analgesia (presentation #3453).
2005, Orlando, Fla. Presented at American Association of Pharmaceutical Scientists Annual
29. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL: Interaction of Meeting and Exposition, Indianapolis, Oct 29-Nov 2, 2000.
St. John’s wort with oral contraceptives: Effects on the 47. Lantz MS, Buchalter E, Giambanco V: St. John’s wort and
pharmacokinetics of norethindrone and ethinyl estradiol, ovarian antidepressant drug interactions in the elderly. J Geriatr Psychiatry
activity and breakthrough bleeding. Contraception 71:402-408, 2005. Neurol 12:7-10, 1999.
30. Hall SD, Wang Z, Huang SM, et al: The interaction between 48. Durr D, Stieger B, Kullak-Ublick GA, et al: St. John’s Wort induces
St John’s wort and an oral contraceptive. Clin Pharmacol Ther intestinal P-glycoprotein/MDR1 and intestinal and hepatic
74:525-535, 2003. CYP3A4. Clin Pharmacol Ther 68:598-604, 2000.
31. Schwarz UI, Buschel B, Kirch W: Unwanted pregnancy on 49. Gordon JB: SSRIs and St. John’s Wort: Possible toxicity? Am Fam
self-medication with St John’s wort despite hormonal contraception. Physician 57:950, 953, 1998.
Br J Clin Pharmacol 55:112-113, 2003. 50. Piscitelli SC, Burstein AH, Chaitt D, et al: Indinavir concentrations
32. Yue QY, Bergquist C, Gerden B: Safety of St John’s wort (Hypericum and St. John’s wort. Lancet 355:547-548, 2000.
perforatum). Lancet 355:576-577, 2000. 51. Sugimoto K, Ohmori M, Tsuruoka S, et al: Different effects of
33. Schulz V: Incidence and clinical relevance of the interactions and St. John’s wort on the pharmacokinetics of simvastatin and
side effects of Hypericum preparations. Phytomedicine 8:152-160, pravastatin. Clin Pharmacol Ther 70:518-524, 2001.
2001. 52. Mai I, Stormer E, Bauer S, et al: Impact of St John’s wort treatment
34. Bauer S, Stormer E, Johne A, et al: Alterations in cyclosporin A on the pharmacokinetics of tacrolimus and mycophenolic acid in
pharmacokinetics and metabolism during treatment with St John’s renal transplant patients. Nephrol Dial Transplant 18:819-822, 2003.
wort in renal transplant patients. Br J Clin Pharmacol 55:203-211, 53. Calapai G, Crupi A, Firenzuoli F, et al: Serotonin, norepinephrine
2003. and dopamine involvement in the antidepressant action of
35. Barone GW, Gurley BJ, Ketel BL, et al: Drug interaction between Hypericum perforatum. Pharmacopsychiatry 34:45-49, 2001.
St. John’s wort and cyclosporin. Ann Pharmacother 34:1013-1016, 54. Groning R, Breitkreutz J, Muller RS: Physico-chemical interactions
2000. between extracts of Hypericum perforatum L. and drugs. Eur J
36. Abul-Ezz SR, Barone GW, Gurley BJ, et al: Effect of herbal Pharm Biopharm 2003;56:231-6.
supplements on cyclosporine blood levels and associated acute 55. Jiang X, Williams KM, Liauw WS, et al: Effect of St John’s wort and
rejection (abstract A3754). Paper presented at the 33rd Annual ginseng on the pharmacokinetics and pharmacodynamics of
Meeting of the American Society of Nephrology, Toronto, October warfarin in healthy subjects. Br J Clin Pharmacol 57:592-599, 2004.
11-16, 2000. 56. Komoroski BJ, Zhang S, Cai H, et al: Induction and inhibition of
37. Mai I, Kruger H, Budde K, et al: Hazardous pharmacokinetic cytochromes p450 by the St. John’s wort constituent hyperforin in
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
interaction of Saint John’s wort (Hypericum perforatum) with the human hepatocyte cultures. Drug Metab Dispos 32:512-518, 2004.
immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 57. Foster BC, Vandenhoek S, Hana J, et al: In vitro inhibition of human
38:500-502, 2000. cytochrome P450-mediated metabolism of marker substrates by
38. Kleber E, Obry T, Hippeli S, et al: Biochemical activities of extracts natural products. Phytomedicine 10:334-342, 2003.
from Hypericum perforatum L. Arzneimittelforschung 49:106-109, 58. Kim RB: Drugs as P-glycoprotein substrates, inhibitors, and inducers.
1999. Drug Metab Rev 34:47-54, 2002.